Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. Ed Silverman, a senior ...

FDA on Friday said it would restrict GLP-1 ingredients Novo, Lilly shares fell after Hims launched the pill on Thursday Hims said the decision followed discussions with stakeholders "Since launching ...

Hims & Hers Health’s stock closed at its lowest level in more than one year, as the company wrapped up a turbulent week in which it sidestepped the regulatory process to launch a cheaper compounded ...

WASHINGTON (AP) — Telehealth company Hims & Hers said Thursday it will launch a cheaper, off-brand version of the weight-loss pill Wegovy, just weeks after drugmaker Novo Nordisk launched its highly ...

When it comes to cancer, waiting for symptoms may soon be old news. Telehealth company Hims & Hers began offering a blood test this week that screens for a wide range of cancers before warning signs ...

NEW YORK, Feb 6 (Reuters) - Hims & Hers (HIMS.N), opens new tab sent a shockwave through the pharmaceutical industry on Thursday with its announcement of a weight-loss pill with a $49-a-month ...

Aaron McDade is a breaking news reporter for Investopedia. He is an experienced journalist who has covered everything from the latest in business and tech news to sports and international news like ...

Novo Nordisk NOVO.B1.58%increase; green up pointing triangle accused Hims & Hers of “illegal mass compounding” after the telehealth platform said it would offer a cheaper, compounded version of the ...

Novo Nordisk (NVO) said on Thursday that it will take legal and regulatory steps in response to plans by Hims & Hers Health (HIMS) to launch low-cost compounded versions of its oral obesity therapy, ...

Telehealth company Hims & Hers has added Grail’s blood cancer test Galleri to its offerings as the medtech has now sent off data for a potential FDA approval. Galleri works as a simple blood test that ...

Advanced cancer detection, hormone therapies and microdoses of GLP-1 sound like medical treatments for the rich and chic. One company is taking them to the Super Bowl so that anyone can try them. Hims ...

Last year, Hims & Hers put out a Super Bowl ad—the first for the telehealth giant—that sparked both support and outrage for the way it claimed that Big Pharma prices GLP-1s “for profits, not patients” ...